4-PrO-MET Under the Microscope: Detectability in the Body

New psychoactive substances (NPS), such as 4-PrO-MET, are chemical modifications of known drugs that mimic their effects. These products are often marketed online as "research chemicals" to exploit legal loopholes. 4-PrO-MET belongs to the tryptamine family, which also includes psilocybin, psilocin, DMT, and endogenous serotonin.

This may pique consumer interest, but clinical studies on this topic are not currently available. This can lead to some uncertainty in the fields of medicine, forensics, and law, as the associated dangers are not always clearly defined, proof is difficult, and the legal situation is constantly changing.

Many psychonauts wonder whether substances they research are detectable in drug screening or drug tests and whether this could lead to problems, for example, with employers. The following blog post aims to clarify some of these uncertainties.

4-PrO-MET is a prodrug that is converted to 4-HO-MET in the body, and its pharmacological effect unfolds by binding to serotonin receptors. This mechanism is the same one through which LSD and psilocin produce their psychedelic effects.

The main difficulty is that the prodrug is rapidly metabolized, mainly producing degradation products, which makes detection difficult.

A 27-year-old person takes 20 mg of 4-PrO-MET as a pellet in the evening. After 45 minutes, strong visual effects, euphoria, and later waves of anxiety occur. Their pulse is 120/min, blood pressure 150/95 mmHg. The sober companion provides calm, fluids, and subdued lighting. After 5 hours, the effects subside.

In the morning, the person notices slight exhaustion. At the general practitioner's office, the standard rapid urine test shows "negative." This does not mean "no intake," but "the test panel does not cover 4-PrO-MET." A targeted LC-MS urine test could still detect 4-HO-MET glucuronides after hydrolysis.

• Regulatory dynamics: Every ban creates evasive maneuvers. Chemically, small changes lead to a legally significant effect, and derivatives of known substances become temporarily legally available as research chemicals.
  
  

• Digital markets: Online shops and forums accelerate the spread of research chemicals, globally and anonymously.
  
  

• Curiosity and self-medication: Some hope for creative, introspective, or mood-lifting effects.
  
  

• Research deficit: For 4-PrO-MET itself, clinical data are lacking. At the same time, psilocybin studies show potential in strictly controlled settings. This discrepancy leads to quick conclusions but is not scientifically transferable.

User reports from forums and case observations show a recurring pattern by which the possible use of 4-PrO-MET in a person can be recognized:

• Sensory enhancement: more intense color perception, heightened enjoyment of music, increased sense of smell
  
  

• Visual effects: slight geometric patterns, "breathing" of walls, occasionally more complex visions at higher doses, more intense colors, patterns, movement impressions on surfaces.
  
  

• Time perception: minutes can seem longer, activities lose or gain depth.
  
  

• Mood: often elevated, warm, connected; can also be anxious with unfavorable set & setting.
  
  

• Cognition: some report a relatively "clear headspace" compared to mushrooms, others report mental flightiness.

• Onset and duration: orally, the effect usually begins after 20–60 minutes, peak between 1.5 and 3 hours, total duration often 4–6 hours, followed by a 1–2-hour come-down phase.

4-PrO-MET is rapidly metabolized to 4-HO-MET. The prodrug is often detectable in blood or plasma for only a short time or not at all. Those who exclusively search for 4-PrO-MET will often find no results. Detection must therefore focus on 4-HO-MET and its metabolites, such as glucuronide conjugates in urine.

• Immunoassays (rapid tests): These common test procedures, which play an important role, for example, in roadside checks, are practically blind to NPS tryptamines. They are tailored to classic panels (opiates, THC, cocaine, amphetamines, etc.).
  
  

• GC-MS (Gas Chromatography-Mass Spectrometry): An analytical method that combines the separation of substances by gas chromatography with their detection by mass spectrometry. Tryptamines such as 4-HO-MET are heat-sensitive. Their decomposition during the analysis process often makes routine analysis difficult and expensive.
  
  

• Gold standard: LC-MS/MS combines liquid chromatography (LC) to separate compounds with tandem mass spectrometry (MS/MS) to identify and quantify them. This sophisticated method combines liquid chromatography and mass spectrometry to avoid thermal degradation while ensuring exceptional sensitivity and selectivity. It enables accurate quantification of free 4-HO-MET and its metabolites and allows indirect measurement of glucuronides in urine.

Many researchers wonder how long 4-PrO-MET or its breakdown products could theoretically be detectable and whether this detectability of 4-PrO-MET could lead to difficulties, for example, at work or in traffic.

• Blood or plasma: Blood tests only provide indications of substance use for a few hours, typically <12 h after consumption.
  
  

• Urine: A urine sample is usually positive for 24–48 h; at higher doses, the detectability of 4-PrO-MET in urine is possible for up to 72 h, especially if glucuronides are measured after hydrolysis of the urine.
  
  

• Hair: depending on hair length, detectability ranges from weeks to months; however, this specialized test is expensive and rarely used for hallucinogens.
  
  

• Saliva: Currently, there are no test strips available that can detect tryptamines, the active ingredient in magic mushrooms, in saliva.
  
  

Consequence: A forensic gap exists. A person can be significantly impaired during the 4–6-hour effect but may test negative on common drug tests the next day. Only a specialized laboratory with LC-MS/MS methods is able to detect even the smallest traces using expensive and complex tests.

Even LC-MS/MS methods are not infallible. Some drug metabolites can have similar mass and fragmentation patterns, leading to false matches by software. Therefore, human expertise is required: plausibility checks with anamnesis and examination, retention times, fragment intensity ratios, and, if necessary, reference standards.

• Emergency Rooms: A negative rapid drug test does not rule out new psychoactive substances (NPS). In cases of suspected intoxication of unclear cause, a toxicological reference laboratory should always be consulted.
  
  

• Occupational Health & Traffic Medicine: The panels of common test strips are blind to 4-PrO-MET. In cases of suspicion, a targeted LC-MS/MS analysis is required.
  
  

• Forensics: Sample logistics matter. Blood as early as possible, urine with and without hydrolysis, and hair for long-term clarification if necessary. Documentation of set & setting, medications, and timeline.

• "Rapid tests find everything." False. 4-PrO-MET detectability is virtually impossible with common drug tests.

• "Natural = safe, synthetic = dangerous." The safety of a substance depends on its dose, quality, purity, context, and the person researching it.
  
  

• "No detection = no effect." False. Detection time and duration of effect do not coincide.
  
  

• "Prodrugs are weak." No. Prodrugs are often merely transport forms. The active substance can be very potent.
  
  

• "A good experience means low danger." False. The potential self-endangerment can only be estimated and is situation-dependent.
  
  

• Rapid tests don't detect everything. 4-PrO-MET usually remains invisible in more superficial drug tests.

• 4-PrO-MET is a tryptamine prodrug that converts to 4-HO-MET in the body.
  
  
• The effects are similar to psilocybin experiences: strongly visual, often mood-enhancing.
  
  
• Dosage: Typical dosage reports are 10–20 mg orally, duration 4–6 hours.
  
  
• The detection problem is central: rapid tests are blind, LC-MS/MS is necessary.
  
  
• The detection window is narrow: in blood only for hours, urine: 1–3 days, hair: long detectability but rarely used method, saliva: the test result is not meaningful.
  
  
• Potential dangers concern the circulatory system and metabolism, psyche, and social contexts; poly-drug use increases them.
  
  
• Clinically: a negative rapid test result is not equivalent to being drug-free.
  
  
• Forensically, early blood and urine samples and a metabolite-centric strategy are needed.
  
  
• Prevention, research, and laboratory expertise are the most effective responses to NPS dynamics.

The landscape of new psychoactive substances (NPS) is constantly changing. The combination of demand for new experiences, rapid online availability, and increasing regulatory pressure means that variants like 4-PrO-MET repeatedly enter the market.

Instead of alarmism, a competent response is needed: improved analytics, clear emergency plans, knowledge of consumption forms, realistic education, and research that carefully distinguishes between the potential medical use of classical psychedelics and the dangers of untested prodrugs.

Until then: anyone confronted with 4-PrO-MET – whether in a clinical, forensic, or private context – should understand the principle of the prodrug, the limitations of conventional drug tests, and the importance of set & setting. This helps to mitigate harm and make more informed decisions in an area that is evolving faster than the evaluation systems designed to assess it.

• Taynah Pereira Galdino, Lucas C. Oliveira, Mateus A. Luz, Raquel Costa Barbosa, Maria C. M. Torres, Katia Sivieri, Paula A. Fernandes, Márcio L. Santos, Antonio G. B. Lima, Suédina M. L. Silva, and Marcus V. L. Fook (2025). Exploring the Frontiers of Psychedelics: A New Chromatographic Method for Detection and Quantification of Psilocybin and Psilocin in Psilocybe cubensis Mushrooms.  https://pubs.acs.org/doi/10.1021/acsomega.5c02751

• Long Yuan a, Christine Huang b, Peggy Liu-Kreyche b, Kimberly Voronin c, R. Marcus Fancher b, Alban Allentoff c, Naiyu Zheng a, Ramaswamy Iyer b, Li Zhu d, Renuka Pillutla a, Qin C. Ji a (2019). A convenient strategy to overcome interference in LC-MS/MS analysis: Application in a microdose absolute bioavailability study. Journal of Pharmaceutical and Biomedical Analysis. Volume 165, 20, 2019, Pages 198-206.